<DOC>
	<DOCNO>NCT01049399</DOCNO>
	<brief_summary>The purpose study determine wether NP031112 safe effective treatment mild moderate Progressive Supranuclear Palsy</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Two Different Oral Doses NP031112 Versus Placebo Treatment Patients With Mild-to-Moderate Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>1 . Men woman diagnosis possible probable PSP accord clinical criterion National Institute Neurologic Diseases Stroke Society PSP ( Appendix 1 ) . 2 . Age 40 85 year ( patient 85 year could include previous assessment Investigator approve sponsor ) . 3 . Brain magnetic resonance imaging ( MRI ) study within 24 month Baseline visit exclude potential cause parkinsonism , especially cerebrovascular lesion space occupy lesion . 4 . Mildtomoderate stage disease severity accord score 1 4 Golbe Staging System . ( Appendix 2 ) 5 . Female patient must surgically sterilize ; least 1 year postmenopausal ( confirm folliclestimulating hormone [ FSH ] &gt; 20 international unit [ IUs ] ) ; use adequate birth control ( implant , injectables , combine oral contraceptive , intrauterine contraceptive device , total sexual abstinence study vasectomise partner ) . Male patient must willing use barrier contraception ( condom ) study 6 month last treatment administration . In European arm study female patient must without childbearing potential . 6 . Caregiver ( dedicate nurse ) living household interact patient &gt; 4 hour every day able assure correct preparation administration study drug . 7 . Patients live home retirement home require continuous nursing care . 8 . General health status acceptable participation 64week clinical trial . 9 . Ability swallow 100 mL water suspension . 10 . Any concomitant medication PSP must welltolerated unchanged least 1 month prior Baseline visit dose regimen maintain study clinical reason modify . 11 . Occupational , physical , respiratory , speech therapy allow must stable least 1 month prior screen . 12 . Pharmacological treatment chronic condition must stable welltolerated least 1 month prior screen . Analgesics , occasional per request nonsteroidal antiinflammatory agent , treatment transient emergent condition allow . 13 . Signed informed consent patient permit prior initiation studyspecific procedure . 1 . Failure perform screen baseline examination . 2 . Hospitalization change chronic concomitant medication 1 month prior screen period ( apart preplanned hospitalization condition , deteriorate since 1 month prior screen period ) . 3 . Clinical , laboratory neuroimaging finding consistent : primary degenerative disease Parkinson 's disease ; dementia Lewy body ; corticobasal degeneration ; frontotemporal dementia ; multiple system atrophy ; parkinsonismdementia complex Guam , Kii Guadeloupe ; Alzheimer 's disease ; amyotrophic lateral sclerosis ; CreutzfeldtJakob Disease ; Huntington 's disease ; Down 's syndrome ; etc . cerebrovascular disease major , strategic multilacunar infarct , extensive white matter lesion score 3 Wahlund 's scale [ Wahlund et al. , 2001 ] . central nervous system disease ( hydrocephalus , severe head trauma , tumour , subdural haematoma relevant space occupy process , etc. ) . epilepsy . infectious , metabolic systemic disease affect central nervous system ( syphilis , present hypothyroidism , present vitamin B12 folate deficiency , clinically significant serum electrolyte disturbance , juvenile onset diabetes mellitus , etc. ) . 4 . A current Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) diagnosis active major depression , schizophrenia bipolar disorder . 5 . Clinically significant , advanced unstable disease may interfere primary secondary variable evaluation , may bias clinical mental assessment put patient special risk , : chronic liver disease , indicate liver function test abnormality ( ALAT , ASAT , bilirubin GGT range ) positive serology Hepatitis C , manifestation liver disease respiratory insufficiency renal insufficiency ( serum creatinine &gt; 2 mg/dL ( &gt; 150 micromol/L ) creatinine clearance &lt; 60 ( accord CockcroftGault formula ) heart disease ( myocardial infarction , unstable angina , heart failure , cardiomyopathy within 6 month screen ) . bradycardia ( heart beat &lt; 50/min ) tachycardia ( heart beat &gt; 95/min ) episode unstable uncontrolled hypertension ( systolic pressure &gt; 160 mm Hg diastolic pressure &gt; 100 mm Hg ) hypotension ( systolic pressure &lt; 90 mm Hg diastolic pressure &lt; 45 mm Hg ) 2 month prior Baseline visit . atrioventricular block ( type II / Mobitz II type III ) , congenital long QT syndrome , sinus node dysfunction prolong QTcF interval ( male &gt; 450 msec female &gt; 470 msec use Fridericia 's formula : QTc = QT/cube root RR ) . uncontrolled diabetes mellitus . malignant tumor within last 5 year except skin malignancy ( melanoma ) indolent prostate cancer . metastasis . 6 . Disability may prevent patient complete study requirement ( e.g. , blindness , deafness , severe language difficulty ) . 7 . Chronic daily drug intake : drug metabolize cytochrome P450 ( CYP ) 3A4 narrow therapeutic window ( acenocoumarol , warfarin , digitoxin ) anticonvulsant indicate epileptic seizure systemic anticholinergic relevant action central nervous system acetylcholinesterase inhibitor neuroleptic except quetiapine , clozapine atypical neuroleptic nootropics piracetam , propentofylline , hydergine , vinpocetine , ginkgo biloba , coenzyme Q10 , idebenone derivative centrally active antihypertensive drug clonidine , alpha methyl dopa , guanidine , guanfacine systemic corticosteroid immunosuppressant systemic nonsteroidal antiinflammatory agent ( except take occasional medication per request acetylsalicylic acid 100 mg/day antiplatelet agent ) . memantine , lithium , valproic acid GSK3 inhibitor within 3 month prior Baseline visit . 8 . Suspected known history drug abuse excessive alcohol intake* 9 . Suspected known allergy component study treatment . 10 . Enrollment another investigational drug study within 3 month Baseline visit . 11 . Any condition , opinion Investigator make patient unsuitable inclusion likely noncompliant . More 21 unit per week men 14 woman ; consumption 8 unit single episode . 1 unit equal approximately 1 glass wine , 250 ml beer 1 shot ( 25 ml ) spirit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>